Core Insights - Heng Rui Medicine has entered into an agreement with Braveheart Bio to license its innovative drug HRS-1893, which is currently in Phase III clinical development for the treatment of obstructive hypertrophic cardiomyopathy (oHCM) [1][2] Group 1 - HRS-1893 is a Myosin selective inhibitor that reduces excessive myocardial contraction by inhibiting ATPase activity, thereby decreasing left ventricular hypertrophy and improving diastolic relaxation [1] - The licensing agreement grants Braveheart Bio exclusive rights to develop, manufacture, and commercialize HRS-1893 globally, excluding mainland China, Hong Kong, Macau, and Taiwan [2] Group 2 - Braveheart Bio will pay a total of $75 million to Heng Rui, which includes a $65 million upfront payment (comprising $32.5 million in cash and $32.5 million in equity) and a $10 million milestone payment upon completion of technology transfer [2] - Heng Rui is eligible to receive up to $1.013 billion in milestone payments related to clinical development and sales, along with sales royalties based on HRS-1893's performance outside the specified regions [2]